Atlas FDA

Alinity m CMV

FDA premarket approval P210022/S009 · decided 2024-02-05

Approval details

PMA number
P210022
Supplement
S009
Supplement type
Real-Time Process
Supplement reason
Labeling Change - Indications/instructions/shelf life/tradename
Trade name
Alinity m CMV
Generic name
Cytomegalovirus (cmv) dna quantitative assay
Applicant
Abbott Molecular, Inc.
Date received
2023-11-15
Decision date
2024-02-05
Days to decision
82 days
Decision code
APPR
Product code
PAB
Advisory committee
Microbiology
Expedited review
No
Location
Des Plaines, IL
Statement
Abbott Molecular Inc. seeks approval to release software version 1.8.0 in the US for a mandatory customer software update.

Class III intelligence, same tools

PMAs share the API, exports and alerts with 510(k) data - watch an applicant and hear about every approval.

510(k) clearances by this applicant

RecordFirmDate
Alinity m HCV (K252102)Abbott Molecular, Inc.2025-09-25
Alinity m EBV (09N43-095) (K243489)Abbott Molecular, Inc.2025-07-28
Alinity m CMV (K243485)Abbott Molecular, Inc.2025-07-01
Alinity m BKV (K241921)Abbott Molecular, Inc.2025-03-24
Alinity m Resp-4-Plex (K241573)Abbott Molecular, Inc.2025-02-14
Alinity m HSV 1 & 2 / VZV (K233349)Abbott Molecular, Inc.2024-05-03
Alinity m STI Assay (K222379)Abbott Molecular, Inc.2023-03-03
Alinity m EBV AMP Kit (List No. 09N43-095), Alinity m EBV CTRL Kit (List No. 09N43-085), Alinity m EBV CAL Kit (List No. 09N43-075) (K212778)Abbott Molecular, Inc.2022-07-15